Introduction
============

Central nervous system (CNS) involvement in AIDS patients is a well-established phenomenon that occurs in approximately 40% to 60% of patients at some stage of the disease. In 10% to 20% of patients, neurologic complications are the first manifestation of HIV infection \[[@B1]\]. The causes of brain involvement include infection, inflammatory changes, and neoplasia \[[@B2]\]. The most common brain lesion in HIV patients worldwide is toxoplasmosis \[[@B3]\], but there is an increased incidence of HIV-associated tuberculosis in focal brain lesions in developing countries \[[@B4]\]. Imaging characteristics of brain lesions in HIV patients have been described \[[@B5],[@B6]\]. The diagnostic yield of brain biopsy in HIV patients has also been evaluated \[[@B7]-[@B9]\]. In recent years, due to the availability of advanced multidrug therapies such as highly active antiretroviral therapy (HAART), the disease has gained more chronic characteristics and patient prognosis has greatly improved. The increased longevity of the clinical course of AIDS patients requires the establishment of more aggressive therapeutic approaches in patients with CNS involvement. Brain lesions detected on imaging studies are treated empirically according to current clinical guidelines. Brain biopsy is indicated in the absence of clinical and radiologic improvement, based on the recommendations of the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the HIV Medicine Association of the Infectious Diseases Society of America. The objective of this retrospective study was to analyze the data of 16 AIDS patients who underwent a brain biopsy at Sheba Medical Center in Israel to evaluate the diagnostic yield and changes in the disease course.

Material and methods
====================

Patient selection and study approval
------------------------------------

The study was conducted according to procedures approved by the Sheba Medical Center Institutional Review Board.

### Clinical data

Sixteen consecutive AIDS patients underwent a brain biopsy at Sheba Medical Center between 1997 and 2009. Patient characteristics; presenting symptoms; neurologic status; CD4 count; radiologic imaging results, including number of lesions, location of the targeted lesion, and presence of post-operative hemorrhage on computed tomography (CT) scans; and pathologic results were retrospectively analyzed. Treatment changes, and clinical and radiologic outcome were recorded.

### Surgical procedure

Stereotactic brain biopsies were performed using a Radionics® CRW™ frame and localizer (except for one patient that underwent an open image-guided navigation system biopsy using pituitary forceps). After performing the CT scan and establishing the target (based on fusion with preoperative MR images and performed by the neurosurgeon), the patient was taken to the operating room and serial stereotactic biopsies were obtained under local anesthesia along the established trajectory using a side-cutting biopsy needle. CT scans were obtained up to 2 hours post-procedure and the patients remained in the neurosurgical department for overnight observation.

### Tissue analysis

Tissue specimens collected in the operation room were placed in individual vials for pathologic analysis; incubated in aerobic, anaerobic, mycobacterium, and fungal cultures; and subjected to PCR analysis for the JC and BK polyomaviruses.

Results
=======

Twelve patients were men. Mean age at onset of the neurologic manifestations was 40.8 years. The clinical manifestations of the disease were mainly cognitive changes and motor deficits. Mean CD4 count before the brain biopsy was 62.6. A total of 19 brain biopsies were performed in 16 patients. In the present series, the initial procedures provided a diagnostic yield of 81.25% (13 diagnostic cases from 16 procedures in 16 patients). Two of these patients underwent repeated biopsies that were eventually diagnostic. If repeated biopsies were taken into consideration, the diagnostic yield was 93.75% (15 diagnostic cases in 16 patients).

Among the three patients with an initially nondiagnostic biopsy, the initial biopsy revealed a nonspecific inflammatory process in two patients, and the procedure was aborted due to hemorrhage in one patient. Two of these patients underwent a repeated biopsy that was eventually diagnostic.

One of the patients initially diagnosed with a nonspecific inflammatory process underwent two more biopsies and the third biopsy was eventually diagnostic. The second patient initially diagnosed with a nonspecific inflammatory process improved with HAART and did not require a second biopsy.

In the present series, the rate of hemorrhagic complications was 10.5% (2 hemorrhages in 19 procedures). Two of our patients had a hemorrhage; the first had a non-surgical bleeding however we had to abort the procedure and the patient underwent later a second procedure with a diagnostic biopsy. The second patient had a diagnostic biopsy, but due to clinical deterioration underwent evacuation of a hematoma. This patient recovered from the procedure, but did not improve with HAART.

Pathologic examination revealed parasitic and fungal infections in 6 patients (6/16) \[38%\]: toxoplasmosis, N = 4 \[67%\], aspergillosis N = 1 \[17%\], and cryptococcosis N = 1 \[17%\]), progressive multifocal leukoencephalopathy (PML) in 4 (25%) patients, AIDS encephalopathy in 4 patients (25%), and lymphoma in 1 (6%) patient. One patient had a nonspecific inflammatory process (6%), The treatment modality was modified in 12 patients and led to clinical and radiologic improvement in 8 patients (Table [1](#T1){ref-type="table"}).

###### 

Patients demographic and clinical data

                                       **Diagnosis**  **Age**   **SBX VS open**   **Sex**   **Solitary vs multiple**      **Target location**       **Side**   **Enhancement**   **Edema**   **Presenting symptoms**   **CD4 pre biopsy**             **Treatment**             **Complications**   **Clinical improvement**
  ---- --------------------------------------------- --------- ----------------- --------- -------------------------- ---------------------------- ---------- ----------------- ----------- ------------------------- -------------------- ----------------------------------- ------------------- --------------------------
     1                                           PML    37            sbx          Male             Multiple                       BG                Right           No            None             Combined                   69                       AZT, 3TC                       No                      No
     2          Non diagnostic × 1,Toxoplasmosis 2nd    36            sbx          Male             Solitary                    Frontal              Right           Yes            Yes               Motor                    50              AZT, 3TC, Antitoxoplasmosis          Bleeding                   No
     3                                           PML    41            sbx          Male             Solitary                       BG                 Left           No            None             Cognitive                  10                       AZT, 3TC                       No                      No
     4                                      Lymphoma    39            sbx          Male             Solitary                       BG                Right           Yes            yes               Motor                    13                   Radiation Therapy                  No                     Yes
     5                                           PML    32            sbx          Male             Multiple                    Frontal              Right           No            None             Combined                   57                         HAART                        No                     Yes
     6                                 Toxoplasmosis    24            sbx          Male             Multiple                       BG                 Left           Yes            Yes             Combined                   38               HAART, Antitoxoplasmosis               No                      No
     7                                 Toxoplasmosis    29            sbx          Male             Solitary                    Frontal              Right           Yes            Yes               Motor                   185               HAART, Antitoxoplasmosis               No                     Yes
     8           Non Diagnostic × 2 Aspergilosis 3rd    78            sbx          Male             Multiple           Parietal occipital frontal    Right           Yes            Yes               Motor                    50                  HAART, Amphotericin                 No                      No
     9                            HIV encephalopathy    33            sbx          Male             Multiple                   Occipital             Right           Yes            Yes             Combined                   3                          HAART                        No                     Yes
    10                                           PML    48            sbx          Male             Multiple                    Frontal              Right           Yes           None             Combined                   25                         HAART                        No                     Yes
    11   Non diagnostic inflamatory reactive process    41            sbx         Female            Multiple                       BG                 Left           Yes            Yes               Motor                    22                         HAART                        No                     Yes
    12                               Viral infection    37            sbx          Male             Multiple                    Frontal               Left           Yes            Yes             Combined                   36                         HAART                        No                      No
    13                                  Cryptoccocal    55            sbx          male             Multiple                    Temporal              Left           Yes            Yes               Motor                    60           HAART, Amphotericin, Intraconazol          No                      No
    14                               Viral infection    46            sbx         Female            Multiple                   Occipital             Right           No            None             Combined                  338                         HAART                        No                     Yes
    15                               Viral infection    46            sbx         Female            Multiple                       BG                Right           Yes            Yes             Combined                   33                         HAART                     Bleeding                   No
    16                                 Toxoplasmosis    32           open         Female            Multiple                    Parietal             Right           Yes            Yes             Combined                   14               HAART, Antitoxoplasmosis               No                     Yes

Discussion
==========

Treatment with highly active antiviral drugs (HAART) has resulted in an overall decline in morbidity and mortality among HIV-infected patients with advanced disease \[[@B10]\]. The widespread use of prophylactic regimens has changed the disease pattern and decreased the incidence of opportunistic infections \[[@B11]\]. Vago et al. \[[@B12]\] reported on a large autopsy series that showed a significant reduction in the frequency of HIV-related central nervous system lesions in AIDS patients since the beginning of the HAART era.

In patients with HIV, *Toxoplasma gondii* is the most frequent infectious cause of focal brain lesions \[[@B3]\]. Toxoplasmic encephalitis has a subacute onset with focal neurologic abnormalities frequently accompanied by headache, altered mental status, and fever \[[@B13]\].

Diffuse toxoplasmosis encephalitis should be considered in patients with anti-*T gondii* immunoglobulin G (IgG) antibodies and CD4 T-cell counts of \<100/μL who present with unexplained neurologic disease.

Since the introduction of HAART, the incidence of toxoplasmic encephalitis has remained stable or decreased, CNS lymphoma has dramatically declined, PML has slightly increased, \[[@B11]\] and the incidence of HIV encephalopathy has increased \[[@B14]\]. Although combination therapies have decreased overall mortality and the prevalence of CNS opportunistic infections, these therapies may be less effective for preventing the direct effects of HIV-1 on the brain. One of our patients presented with histologic features of AIDS encephalopathy. The majority of patients in our cohort were men with a median age of 40, consistent with other studies \[[@B15],[@B16]\]. These findings are compatible with our data , which is reported to be increasing in prevalence in the HAART era \[[@B17]\].

Thallium SPECT and PET scanning in the diagnosis of lymphoma and PCR analysis of the cerebrospinal fluid for the diagnosis of toxoplasmosis and JC virus have led to a shift in the use invasive diagnostic techniques (brain biopsy) to noninvasive diagnostic methods \[[@B5]\]. The patient in our series that was diagnosed with lymphoma had a solitary enhancing lesion. Although CNS lymphoma generally tends to enhance, atypical characteristics may be observed on MR images of immunocompromised patients \[[@B18]\]. Toxoplasma and lymphoma may have similar appearance on MR imaging. Erdag et al. \[[@B18]\] noted that lymphoma usually appears as a solitary lesion, unlike toxoplasmosis, which appears as a multifocal lesion. Only half of our patients with toxoplasmosis, however, had multifocal disease, similar to a previous report \[[@B15]\].

The majority of patients in our cohort that were diagnosed with PML had nonenhancing lesions, consistent with previous studies \[[@B18],[@B19]\]. Other studies, however, report enhancement on MR images of PML patients that may reach 42% \[[@B15]\], and the development of a mass effect and temporary enhancement on MR images in the early phase of treatment might represent positive predictive factors for prolonged survival \[[@B19]\].

A literature review revealed several descriptions of stereotactic brain biopsy in AIDS patients. The majority of these were reports on patients treated in the pre-HAART era \[[@B7]-[@B9],[@B16],[@B20]-[@B26]\]. In a recent study, Rosenow et al. \[[@B15]\] divided a large cohort of 246 patients that underwent brain biopsy into two diagnostic groups, before and after the HAART era. The authors concluded that the introduction of HAART led to a steep decrease in the number of biopsies performed annually. Biopsy led to an objective and definitive diagnosis in 96% of patients (48/50), in the patients in the HAART era. Definitive diagnoses were obtained for 91.3% of patients (179/196) in the pre-HAART era. The overall diagnostic yield of biopsy was 92.3% of the total patient cohort. Rosenow et al. \[[@B15]\] suggested that AIDS patients with intra-cerebral lesions should undergo toxoplasmosis titers, and those with negative toxoplasmosis titers should undergo early brain biopsy. In our study, the majority of the patients were treated in the HAART era, which may correlate with the relatively small cohort of patients that underwent stereotactic brain biopsy. The diagnostic yield of the biopsy was high, although lower than previously reported \[[@B15]\].

A total of 19 biopsies were performed in 16 patients; one procedure was aborted due to bleeding and three biopsies were nondiagnostic (15%). Significantly, two patients underwent repeated biopsies that were conclusive. Diagnoses were eventually obtained for 93.7% of patients (15/16). Based on the biopsy findings, the treatment modality was modified in 12 patients and led to clinical and radiologic improvement in 8 patients. Modification of the treatment following brain biopsy has also been reported \[[@B1],[@B8]\].

Hemorrhagic complications of biopsy are reported \[[@B16],[@B20],[@B23],[@B25]\]. The incidence of hemorrhage in our small cohort of patients was higher than that reported in a non-HIV group of patients treated in our department \[[@B27]\]. Although the coagulation profile in our patients was within normal limits, there may have been undetectable coagulopathy in this group of patients. Anticoagulopathy regimens have been suggested by others \[[@B16]\] and pre-biopsy correction of thrombopenia less than 100,000/ml is suggested by Rosenow et al. \[[@B15]\]. A larger cohort of patients is required to establish more definitive conclusions.

Conclusion
==========

We present the results from a single institute HAART era brain biopsy study in a cohort of 16 patients with active AIDS-associated lesions. Our objective diagnostic rates are consistent with those previously reported, allowing for treatment modification and confirming the usefulness of biopsy in these patients.
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